To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia
Intervention: Comparator: atorvastatin (Drug); Comparator: Placebo (Drug); Comparator: ezetimibe (Drug); Comparator: Placebo. (Drug)
Phase: Phase 3
Sponsored by: Merck Sharp & Dohme Corp.
Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.
The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe
plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high
risk for coronary heart disease not adequately controlled on atorvastatin 20 mg.
Official title: A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6
Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
Percent Change From Baseline in Total-Cholesterol at Week 6
Percent Change From Baseline in Triglycerides (TG) at Week 6
Percent Change From Baseline in Apolipoprotein B at Week 6
Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6
Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6
Minimum age: 18 Years.
Maximum age: 79 Years.
- Patient with LDL-C >100 mg/dL & on a stable dose of atorvastatin 20 mg
- Pregnant or lactating women or intending to become pregnant
- Patient with sensitivity or intolerance to ezetimibe or atorvastatin
- Patient with diabetes or coronary heart disease
Locations and Contacts
MedWatch - FDA maintained medical product safety Information
Merck: Patient & Caregiver U.S. Product Web Site
Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol. 2008 Dec 1;102(11):1489-94. doi: 10.1016/j.amjcard.2008.09.075. Epub 2008 Oct 23.
Starting date: February 2006
Last updated: October 31, 2014